These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. The cost-effectiveness of cardiovascular medicine in Greece: brief notes. Vardas PE Hellenic J Cardiol; 2012; 53(4):333-4. PubMed ID: 22796825 [No Abstract] [Full Text] [Related]
6. [The elderly cardiovascular patient in general practice. Health care costs--drugs--economic feasibility]. Schmidt K Fortschr Med; 1996 Mar; 114(7):43-4. PubMed ID: 8900969 [No Abstract] [Full Text] [Related]
7. Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Terminology I would like to see disappear. Detsky AS Am Heart J; 1999 May; 137(5):S51-2. PubMed ID: 10220597 [No Abstract] [Full Text] [Related]
9. Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Product labeling and pharmacoeconomic information. Morris LA Am Heart J; 1999 May; 137(5):S78-80. PubMed ID: 10220603 [No Abstract] [Full Text] [Related]
10. Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Evaluating the economic implications of cardiovascular therapeutics. Califf RM Am Heart J; 1999 May; 137(5):S35-7. PubMed ID: 10220593 [No Abstract] [Full Text] [Related]
12. Proceedings of a symposium: economics and cost-effectiveness in evaluating the value of cardiovascular therapies. What constitutes a useful health economic study for the pharmaceutical industry? Gagnon JP Am Heart J; 1999 May; 137(5):S62-6. PubMed ID: 10220599 [No Abstract] [Full Text] [Related]
13. Beneficiaries with cardiovascular disease and thePart D coverage gap. Polinski JM; Shrank WH; Glynn RJ; Huskamp HA; Roebuck MC; Schneeweiss S Circ Cardiovasc Qual Outcomes; 2012 May; 5(3):387-95. PubMed ID: 22511746 [TBL] [Abstract][Full Text] [Related]
14. Improving Adherence to Cardiovascular Therapies: An Economic Evaluation of a Randomized Pragmatic Trial. Smith DH; O'Keeffe-Rosetti M; Owen-Smith AA; Rand C; Tom J; Vupputuri S; Laws R; Waterbury A; Hankerson-Dyson DD; Yonehara C; Williams A; Schneider J; Dickerson JF; Vollmer WM Value Health; 2016; 19(2):176-84. PubMed ID: 27021751 [TBL] [Abstract][Full Text] [Related]
15. The Canadian Cardiovascular Society and reference-based drug pricing. Olley PM; McLaughlin PR Can J Cardiol; 1998 May; 14(5):669-70. PubMed ID: 9627521 [No Abstract] [Full Text] [Related]
17. The cost-effectiveness of cardiovascular medicine: victims of our own success? Vardas PE Hellenic J Cardiol; 2013; 54(2):155-6. PubMed ID: 23557621 [No Abstract] [Full Text] [Related]
18. Cardiovascular disease in primary care: concordance and risk reduction. Knapton M Br J Gen Pract; 2012 Jun; 62(599):284-5. PubMed ID: 22687202 [No Abstract] [Full Text] [Related]
19. The Imminent Demise of Cardiovascular Drug Development. Packer M JAMA Cardiol; 2017 Dec; 2(12):1293-1294. PubMed ID: 29117286 [No Abstract] [Full Text] [Related]
20. What future does the pharmaceutical industry have in the cardiovascular world? Braunwald E Eur Heart J; 2013 Apr; 34(13):943-4. PubMed ID: 23546415 [No Abstract] [Full Text] [Related] [Next] [New Search]